Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational... Oncol Ther (2018) 6:203–215 https://doi.org/10.1007/s40487-018-0064-8 ORIGINAL RESEARCH Real-World EGFR T790M Testing in Advanced Non- Small-Cell Lung Cancer: A Prospective Observational Study in Japan . . . Takashi Seto Naoyuki Nogami Nobuyuki Yamamoto . . . . Shinji Atagi Naoki Tashiro Yoko Yoshimura Yutaka Yabuki Hideo Saka Received: July 3, 2018 / Published online: August 28, 2018 The Author(s) 2018 advanced/metastatic NSCLC who reported dis- ABSTRACT ease progression during treatment with first- or second-generation EGFR TKIs. Data regarding Introduction: Approximately one-half of sampling methods for T790M mutation testing patients with epidermal growth factor receptor (plasma sample, cytology or tissue biopsy) and (EGFR) mutation-positive advanced/metastatic the treatment strategies after disease progres- non-small-cell lung cancer (NSCLC) develop sion were recorded prospectively. resistance to first- or second-generation EGFR Results: A total of 236 patients were included tyrosine kinase inhibitors (TKIs) due to a sec- in the study (female, 67.4%; median age, ondary T790M mutation. This study investi- 73.0 years), and 205 patients (86.9%) under- gated the pattern of T790M testing after EGFR went rebiopsy by any of the three possible TKI treatment in a real-world setting in Japan. methods: plasma sampling in 137 patients Method: This prospective observational study (58.1%) and tissue/cytology sampling http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Loading next page...
 
/lp/springer-journals/real-world-egfr-t790m-testing-in-advanced-non-small-cell-lung-cancer-a-IcG010cRE0

References (37)

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0064-8
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:203–215 https://doi.org/10.1007/s40487-018-0064-8 ORIGINAL RESEARCH Real-World EGFR T790M Testing in Advanced Non- Small-Cell Lung Cancer: A Prospective Observational Study in Japan . . . Takashi Seto Naoyuki Nogami Nobuyuki Yamamoto . . . . Shinji Atagi Naoki Tashiro Yoko Yoshimura Yutaka Yabuki Hideo Saka Received: July 3, 2018 / Published online: August 28, 2018 The Author(s) 2018 advanced/metastatic NSCLC who reported dis- ABSTRACT ease progression during treatment with first- or second-generation EGFR TKIs. Data regarding Introduction: Approximately one-half of sampling methods for T790M mutation testing patients with epidermal growth factor receptor (plasma sample, cytology or tissue biopsy) and (EGFR) mutation-positive advanced/metastatic the treatment strategies after disease progres- non-small-cell lung cancer (NSCLC) develop sion were recorded prospectively. resistance to first- or second-generation EGFR Results: A total of 236 patients were included tyrosine kinase inhibitors (TKIs) due to a sec- in the study (female, 67.4%; median age, ondary T790M mutation. This study investi- 73.0 years), and 205 patients (86.9%) under- gated the pattern of T790M testing after EGFR went rebiopsy by any of the three possible TKI treatment in a real-world setting in Japan. methods: plasma sampling in 137 patients Method: This prospective observational study (58.1%) and tissue/cytology sampling

Journal

Oncology and TherapySpringer Journals

Published: Aug 28, 2018

There are no references for this article.